AstraZeneca PLC (LON:AZN - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of £114.96 ($142.06) and traded as high as £119.78 ($148.02). AstraZeneca shares last traded at £117.86 ($145.65), with a volume of 2,997,711 shares.
Wall Street Analyst Weigh In
A number of research firms have weighed in on AZN. JPMorgan Chase & Co. restated an "overweight" rating and set a £140 ($173.01) price objective on shares of AstraZeneca in a research report on Friday, November 22nd. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, Berenberg Bank reaffirmed a "buy" rating and issued a GBX 140 ($1.73) price target on shares of AstraZeneca in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of GBX 7,935.67 ($98.07).
Read Our Latest Stock Analysis on AstraZeneca
AstraZeneca Stock Performance
The company has a market cap of £179.55 billion, a price-to-earnings ratio of 3,677.46, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The stock's fifty day simple moving average is £107.76 and its 200 day simple moving average is £114.90.
Insiders Place Their Bets
In other AstraZeneca news, insider Pascal Soriot bought 20,000 shares of the business's stock in a transaction on Thursday, November 14th. The stock was bought at an average price of £102.03 ($126.09) per share, with a total value of £2,040,600 ($2,521,749.88). Also, insider Tony Mok purchased 1,500 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of £126.80 ($156.70) per share, for a total transaction of £190,200 ($235,046.96). Corporate insiders own 0.04% of the company's stock.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Recommended Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
